BioVaxys Technology Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BVAXF research report →
Price Chart
About the company
BioVaxys Technology Corp. (BVAXF) is a clinical-stage biotechnology company primarily engaged in the development of innovative vaccine platforms targeting both antiviral diseases and various forms of cancer. Its product pipeline features several key candidates, including two SARS-CoV-2 vaccines: BVX-0320, a monovalent version, and BVX-0121, a multivalent option.
- CEO
- James Christopher Passin
- IPO
- 2018
- Employees
- 3
- HQ
- Etobicoke, ON, CA
Get TickerSpark's AI analysis on BVAXF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.60M
- P/E
- -0.91
- PEG
- 0.04
- P/S
- 0.00
- P/B
- -0.56
- EV/EBITDA
- -0.99
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 69.89%
- ROIC
- 61.28%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-3,122,149
- Net Income
- $-3,954,781+48.6%
- EPS
- $-0.20+64.7%
- OCF Growth
- -76.5%
- FCF Growth
- -176.7%
- 52W High
- $0.27
- 52W Low
- $0.02
- 50D MA
- $0.12
- 200D MA
- $0.12
- Beta
- 1.09
- RSI (14)
- 46
- Avg Volume
- 31.31K
No earnings-call transcripts are available for BVAXF yet.
- Free Float
- 89.7%
- Shares Outstanding
- 29.15M
- Float Shares
- 26.14M
Our BVAXF coverage
Recent articles, reports, and earnings notes.
No research on BVAXF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BVAXF report →BioVaxys Presents Further Validation of the Robust Immune Response from a Combination of MVP-S with Checkpoint Inhibitors and Low-Dose Cyclophosphamide in Ovarian Cancer
thenewswire.com · May 1
BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update
thenewswire.com · Apr 28
BioVaxys Announces Phase I/II PESCO Trial Abstract Accepted for Presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
thenewswire.com · Apr 27
BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update
thenewswire.com · Apr 13
BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update
thenewswire.com · Mar 31
BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update
thenewswire.com · Mar 17
BioVaxys Announces Application for Management Cease Trade Order
thenewswire.com · Mar 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.